Author: PharmaTimes

GlaxoSmithKline says that the US Food and Drug Administration has given the green light an expanded label for its anti-cancer therapy, Bexxar (tositumomab and I131), to include patients with relapsed or refractory low-grade non-Hodgkin’s lymphoma, including those that have failed on an alternative treatment.

Merck & Co’s share price took another knocking in New York yesterday after US Food and Drug Administration scientist, Dr David Graham, said he was significantly upping his estimates on the number of patients that were harmed as a result of taking the company’s now withdrawn painkiller, Vioxx (rofecoxib) [[01/10/04a]].

Pfizer has been hit by a class action lawsuit in the USA, claiming that the world’s largest pharmaceutical firm broke the law by misleading investors about the safety of its top-selling painkiller, Celebrex (celecoxib).

Clinical researchers in the Americas have got until Friday 29 January to submit their essay for the Clinical Researcher of the Year – The Americas 2016 competition

Clinical researchers in the Americas have got until Friday 29 January to submit their essay for the Clinical Researcher of the Year – The Americas 2016 competition